Clinical Pharmacology of Antimicrobials: Focus on the Safety of Vancomycin and Linezolid
https://doi.org/10.30895/2312-7821-2023-337
Abstract
Scientific relevance. Vancomycin and linezolid are the antibacterial agents of choice for severe infections caused by multidrug-resistant pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). However, few studies have been conducted in Russia to analyse the safety of these medicinal products.
Aim. The study aimed to compare the safety of vancomycin and linezolid using the Moscow segment of the Russian Federal Service for Surveillance in Healthcare’s database for adverse drug reaction (ADR) reports.
Materials and methods. The study used information from the spontaneous reporting database for 2018–2022, which contained 147 ADR reports for vancomycin (122 reports) and linezolid (25 reports). The authors analysed the ADR distribution and assessed the statistical significance of the identified differences by sex, weight, and age of patients, conditions of medical care, route of administration, single dose, daily dose, therapy duration, ICD-10 codes, ADR severity, and ADR outcome.
Results. The distribution of adverse reactions to vancomycin and linezolid by patient age was relatively uniform. Outpatient linezolid was associated with a significantly higher rate of ADRs (3 of 5 reports) than outpatient vancomycin (21 of 129 reports; p=0.0408). For ADR severity, 5 of 20 ADRs reported with linezolid required hospitalisation or prolongation of hospitalisation—considerably more than with vancomycin (16 of 94 reports; p=0.528). The average single dose of vancomycin (794 mg) was higher than that of linezolid (467 mg; p=0.007); the same was noted for average daily doses (1273 mg vs 998 mg; p=0.3664). The mean duration of treatment with linezolid before ADR onset was 5.26 days, which was significantly longer than the mean duration of treatment with vancomycin (2.44 days; p=0.0053). Oral linezolid was associated with a significantly higher ADR rate (4 of 19 cases) than oral vancomycin (5 of 96 cases; p=0.0027).
Conclusions. The ADRs observed with vancomycin and linezolid were predictable and class-specific. According to the results of the ADR report analysis, adverse reactions to vancomycin and linezolid were associated with different factors. Similar results of the literature analysis confirmed this conclusion. However, according to the results of the linear regression analysis, none of the factors considered in this study had a statistically significant influence on the probability of developing an adverse reaction to vancomycin or linezolid.
Keywords
About the Authors
M. V. ZhuravlevaRussian Federation
Marina V. Zhuravleva, Dr. Sci. (Med.), Professor
8/2 Petrovsky Blvd., Moscow 127051
11 Yauzskaya St., Moscow 109240
E. V. Kuznetsova
Russian Federation
Elena V. Kuznetsova
30 Bolshaya Tatarskaya St., Moscow 115184
N. G. Berdnikova
Russian Federation
Nadezhda G. Berdnikova, Cand. Sci. (Med.)
11 Yauzskaya St., Moscow 109240
A. B. Prokofiev
Russian Federation
Alexey B. Prokofiev, Dr. Sci. (Med.), Professor
8/2 Petrovsky Blvd., Moscow 127051
11 Yauzskaya St., Moscow 109240
T. R. Kameneva
Russian Federation
Tatiana R. Kameneva, Cand. Sci. (Med.), Associate Professor
30 Bolshaya Tatarskaya St., Moscow 115184
2/1 Kashtanovaya Aly, Zelenograd, Moscow 124489
E. Yu. Demchenkova
Russian Federation
Elena Yu. Demchenkova, Cand. Sci. (Pharm.)
8/2 Petrovsky Blvd., Moscow 127051
11 Yauzskaya St., Moscow 109240
References
1. Dhingra-Kumar N, Brusaferro S, Arnoldo L. Patient safety in the world. In: Donaldson L, Ricciardi W, Sheridan S, Tartaglia R, eds. Textbook of patient safety and clinical risk management. Cham (CH); 2021. P. 93–8. https://doi.org/10.1007/978-3-030-59403-9_8
2. Gabrielyan NI, Sharapchenko SO, Kisil OV, Kormilitsina VG, Drabkina IV, Safonova ТB, et al. The problem of global development of antibiotic resistant nosocomial pathogens. Therapeutic Archive. 2020;(11):110–6 (In Russ.). https://doi.org/10.26442/00403660.2020.11.000783
3. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bac teremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53–9. https://doi.org/10.1086/345476
4. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55. https://doi.org/10.1093/cid/ciq146
5. Chastre J, Blasi F, Masterton RG, Rello J, Torres A, Welte T. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect. 2014;20 Suppl 4:19–36. https://doi.org/10.1111/1469-0691.12450
6. Ye ZK, Chen YL, Chen K, Zhang XL, Du GH, He B, et al. Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. J Antimicrob Chemother. 2016;71(11):3020–5. https://doi.org/10.1093/jac/dkw254
7. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99–110. https://doi.org/10.2165/11539220-000000000-00000
8. Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother. 2012;67(6):1305–10. https://doi.org/10.1093/jac/dks066
9. Rice TL. Simplified dosing and monitoring of vancomycin for the burn care clinician. Burns. 1992;18(5):355–61. https://doi.org/10.1016/0305-4179(92)90032-p
10. Kees MG, Wicha SG, Seefeld A, Kees F, Kloft C. Unbound fraction of vancomycin in intensive care unit patients. J Clin Pharmacol. 2014;54(3):318–23. https://doi.org/10.1002/jcph.175
11. Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013;52(1):1–8. https://doi.org/10.1007/s40262-012-0018-5
12. Basalai ON, Bushma MI. Toxic nephropathy: pathogenesis, treatment, prevention. Meditsinskie novosti. 2017;(8):7–10 (In Russ.). EDN: ZDUQBT
13. Bruniera FR, Ferreira FM, Saviolli LRM, Bacci MR, Feder D, da Luz Gonçalves Pedreira M, et al. The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci. 2015;19(4):694–700. PMID: 25753888
14. Bergeron L, Boucher FD. Possible red-man syndrome associated with systemic absorption of oral vancomycin in a child with normal renal function. Ann Pharmacother. 1994;28(5):581–4. https://doi.org/10.1177/106002809402800505
15. Baumgartner LJ, Brown L, Geier C. Hypersensitivity reaction following administration of low-dose oral vancomycin for the treatment of clostridium difficile in a patient with normal renal function. J Pharm Pract. 2017;30(6):650–2. https://doi.org/10.1177/0897190016668437
16. Barron J, Lattes A, Marcus EL. Rash induced by enteral vancomycin therapy in an older patient in a long-term care ventilator unit: case report and review of the literature. Allergy Asthma Clin Immunol. 2018;14:73. https://doi.org/10.1186/s13223-018-0293-2
17. Pettit NN, DePestel DD, Fohl AL, Eyler R, Carver PL. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection. Pharmacotherapy. 2015;35(2):119–26. https://doi.org/10.1002/phar.1538
18. Wang X, Wang Y, Yao F, Chen S, Hou Y, Zheng Z, et al. Pharmacokinetics of linezolid dose adjustment for creatinine clearance in critically ill patients: a multicenter, prospective, open-label, observational study. Drug Des Devel Ther. 2021;15:2129–41. https://doi.org/10.2147/DDDT.S303497
19. Sazdanovic P, Jankovic SM, Kostic M, Dimitrijevic A, Stefanovic S. Pharmacokinetics of linezolid in critically ill patients. Expert Opin Drug Metab Toxicol. 2016;12(6):595–600. https://doi.org/10.1517/17425255.2016.1170807
20. Hashemian SMR, Farhadi T, Ganjparvar M. Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther. 2018;12:1759–67. https://doi.org/10.2147/DDDT.S164515
21. Tsuji Y, Holford NHG, Kasai H, Ogami C, Heo YA, Higashi Y, et al. Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. Br J Clin Pharmacol. 2017;83(8):1758–72. https://doi.org/10.1111/bcp.13262
22. Bayram N, Düzgöl M, Kara A, Özdemir FM, Devrim İ. Linezolid-related adverse effects in clinical practice in children. Arch Argent Pediatr. 2017;115(5):470–5. https://doi.org/10.5546/aap.2017.eng.470
23. Shikh EV, Morozova TE, Drozdov VN, Lazareva NB, Shatsky DA, Andrushchyshina TB, et al. Antimicrobial treatment of infective endocarditis, caused by Enterococcus faecalis. Rational Pharmacotherapy in Cardiology. 2019;15(4):586–92 (In Russ.). https://doi.org/10.20996/1819-6446-2019-15-4-586-592
24. Vlasova AV, Smirnova EV, Gorev VV, Sychev DA. Adverse reactions in children to antimicrobials: limitations of the spontaneous reporting method and the possibilities of the global trigger method for drug-induced conditions. Farmateka. 2023;30(1–2):18–31 (In Russ.). https://doi.org/10.18565/pharmateca.2023.1-2.18-31
25. Ioannidou M, Apostolidou-Kiouti F, Haidich AB, Niopas I, Roilides E. Efficacy and safety of linezolid for the treatment of infections in children: a meta-analysis. Eur J Pediatr. 2014;173(9):1179–86. https://doi.org/10.1007/s00431-014-2307-5
26. Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J. 2003;22(8):677–86. https://doi.org/10.1097/01.inf.0000078160.29072.42
27. Pletz MW, Burkhardt O, Welte T. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? Comparison of pharmacology and clinical efficacy. Eur J Med Res. 2010;15(12):507–13. https://doi.org/10.1186/2047-783x-15-12-507
Supplementary files
Review
For citations:
Zhuravleva M.V., Kuznetsova E.V., Berdnikova N.G., Prokofiev A.B., Kameneva T.R., Demchenkova E.Yu. Clinical Pharmacology of Antimicrobials: Focus on the Safety of Vancomycin and Linezolid. Safety and Risk of Pharmacotherapy. 2023;11(4):430-441. (In Russ.) https://doi.org/10.30895/2312-7821-2023-337